These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32551010)

  • 1. Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.
    Teng M; Ficarro SB; Yoon H; Che J; Zhou J; Fischer ES; Marto JA; Zhang T; Gray NS
    ACS Med Chem Lett; 2020 Jun; 11(6):1269-1273. PubMed ID: 32551010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
    Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
    Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
    Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
    J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.
    Yasui T; Yamamoto T; Sakai N; Asano K; Takai T; Yoshitomi Y; Davis M; Takagi T; Sakamoto K; Sogabe S; Kamada Y; Lane W; Snell G; Iwata M; Goto M; Inooka H; Sakamoto JI; Nakada Y; Imaeda Y
    Bioorg Med Chem; 2017 Sep; 25(17):4876-4886. PubMed ID: 28760529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of BCL6 in non-Hodgkin lymphoma by insertion of IGH sequences in complex translocations involving band 3q27.
    Chaganti SR; Rao PH; Chen W; Dyomin V; Jhanwar SC; Parsa NZ; Dalla-Favera R; Chaganti RS
    Genes Chromosomes Cancer; 1998 Dec; 23(4):328-36. PubMed ID: 9824206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
    McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
    ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
    Kerres N; Steurer S; Schlager S; Bader G; Berger H; Caligiuri M; Dank C; Engen JR; Ettmayer P; Fischerauer B; Flotzinger G; Gerlach D; Gerstberger T; Gmaschitz T; Greb P; Han B; Heyes E; Iacob RE; Kessler D; Kölle H; Lamarre L; Lancia DR; Lucas S; Mayer M; Mayr K; Mischerikow N; Mück K; Peinsipp C; Petermann O; Reiser U; Rudolph D; Rumpel K; Salomon C; Scharn D; Schnitzer R; Schrenk A; Schweifer N; Thompson D; Traxler E; Varecka R; Voss T; Weiss-Puxbaum A; Winkler S; Zheng X; Zoephel A; Kraut N; McConnell D; Pearson M; Koegl M
    Cell Rep; 2017 Sep; 20(12):2860-2875. PubMed ID: 28930682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL6 as a therapeutic target for lymphoma.
    Leeman-Neill RJ; Bhagat G
    Expert Opin Ther Targets; 2018 Feb; 22(2):143-152. PubMed ID: 29262721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation.
    Yang H; Green MR
    Front Cell Dev Biol; 2019; 7():272. PubMed ID: 31788471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
    Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
    J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells.
    Niu H; Cattoretti G; Dalla-Favera R
    J Exp Med; 2003 Jul; 198(2):211-21. PubMed ID: 12860928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl6 middle domain repressor function is required for T follicular helper cell differentiation and utilizes the corepressor MTA3.
    Nance JP; Bélanger S; Johnston RJ; Hu JK; Takemori T; Crotty S
    Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13324-9. PubMed ID: 26460037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.
    Margalit O; Amram H; Amariglio N; Simon AJ; Shaklai S; Granot G; Minsky N; Shimoni A; Harmelin A; Givol D; Shohat M; Oren M; Rechavi G
    Blood; 2006 Feb; 107(4):1599-607. PubMed ID: 16249378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
    Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
    J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of BCL6 during germinal center B cell development.
    Huang C; Melnick A
    Sci China Life Sci; 2015 Dec; 58(12):1226-32. PubMed ID: 26566802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
    Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
    Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.
    Madapura HS; Nagy N; Ujvari D; Kallas T; Kröhnke MCL; Amu S; Björkholm M; Stenke L; Mandal PK; McMurray JS; Keszei M; Westerberg LS; Cheng H; Xue F; Klein G; Klein E; Salamon D
    Oncogene; 2017 Aug; 36(32):4619-4628. PubMed ID: 28368400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.